Literature DB >> 10757443

Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.

A M Codegoni1, F Bertoni, G Colella, G Caspani, L Grassi, M D'Incalci, M Broggini.   

Abstract

The loss of mismatch repair enzymes increases the mutation rate in microsatellites and coding regions of the genome and appears to be involved in drug resistance. The replication error (RER+) phenotype, associated with microsatellite instability, has been widely described for both familial and sporadic colon cancers and for gastric and endometrial tumors. For ovarian cancer, the incidence of RER+ cases among sporadic tumors is still uncertain. We analyzed epithelial ovarian tumors and ovarian carcinoma cell lines for microsatellite instability and for mutations in the coding regions of different genes, including the recently discovered human CHK-1 gene, which has an important role in controlling cell cycle progression and whose coding region contains a poly(A)9 tract. Microsatellite instability and frameshift mutations in coding regions of BAX, TGFbetaRII, IGFIIR, E2F-4, ICE, and CHK-1 genes were analyzed in ovarian cancer samples and cell lines by polymerase chain reaction (PCR). Approximately 26% of patients showed microsatellite instability in two or more loci. BAT-26 locus showed no alteration in primary tumors. We detected a BAX mutation in one tumor sample and a TGFbetaRII mutation in one cell line. Our findings confirm the presence of the RER+ phenotype in sporadic ovarian cancer. The low rate of mutation in genes previously reported to be altered in colon and gastric cancer suggests that other not yet identified genes might be altered and could play a role in tumor progression and response to treatment in RER+ ovarian tumors.

Entities:  

Mesh:

Year:  1999        PMID: 10757443

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  8 in total

1.  Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.

Authors:  S Dholariya; R Mir; M Zuberi; P Yadav; G Gandhi; N Khurana; A Saxena; P C Ray
Journal:  Clin Transl Oncol       Date:  2015-07-25       Impact factor: 3.405

2.  Modeling variation in tumors in vivo.

Authors:  James R Stringer; Jon S Larson; Jared M Fischer; Mario Medvedovic; Megan N Hersh; Gregory P Boivin; Saundra L Stringer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-03       Impact factor: 11.205

Review 3.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 4.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

Review 5.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

Review 6.  Checkpoint kinase 1 in DNA damage response and cell cycle regulation.

Authors:  Mallikarjun Patil; Navjotsingh Pabla; Zheng Dong
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

7.  A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer.

Authors:  Y Watanabe; M Koi; H Hemmi; H Hoshai; K Noda
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

Review 8.  Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability.

Authors:  Madhura Deshpande; Phillip A Romanski; Zev Rosenwaks; Jeannine Gerhardt
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.